indication that a good response to prednisolone can be expected in wheezy patients.
The objective responses to bronchodilator drugs are commonly used in the assessment of patients with airways obstruction. Isoprenaline given by inhalation is considered by many physicians to be the most effiCient short-acting bronchodilator drug and would therefore appear to be the drug of choice for assessing the degree of reversible airways obstruction. The response to isoprenaline and other bronchodilator drugs, however, varies according to the severity of 'bronchospasm' at the time of the test (Hume and Gandevia, 1957; Hume and Rhys Jones, 1961) . Some clinicians prefer adrenaline to isoprenaline. It has been reported that the injection of adrenaline has little or no advantage over the inhalation route in asthmatic patients not in severe status asthmaticus (Kennedy, 1961) .
Aminophylline is frequently used in the treatment of wheezy patients, but little information is available about its efficacy compared with other bronchodilator drugs.
Cholinergic drugs have long been known to have bronchodilator properties (Finnegan, 1950) , and it has been suggested that there are different responses to atropine in asthma and in chronic bronchitis, the variation in response having some correlation with the response to corticosteroid drugs (Altounyan, 1964) .
There is now no doubt about the benefit of corticosteroid drugs in the treatment of some asthmatic patients (Thursby-Pelham and Kennedy, 1958; Somner, Rogan, and Grant, 1960; Phear, Ball, and Page, 1960) , but their place in the treatment of wheezy chronic bronchitis is less clear. It is sometimes difficult to differentiate clinically between patients with wheezy chronic bronchitis and patients suffering from chronic asthma, and because of this it is common practice to give a trial of corticosteroid drugs to most wheezy patients. By doing this a few patients thought to have chronic bronchitis are found to respond dramatically-as judged by the objective assessment of ventilatory function tests-and it is likely that this small group of patients have chronic asthma as their dominant disease and not chronic bronchitis. It may be argued that corticosteroid drugs can, in fact, be dangerous when given to patients suffering from chronic bronchitis, especially in relation to hospital infection. Also a patient's stay in hospital is usually lengthened when corticosteroid drug assessment is performed. It would therefore be of considerable value if some indication could be obtained of a wheezy patient's probable response to corticosteroid drugs from the results of tests using simple bronchodilator drugs. With these points in mind, it was decided to assess the effects of some commonly used bronchodilator drugs and prednisolone in patients suffering from chronic bronchitis and chronic asthma.
MATERIAL
Two groups of wheezy patients were selected for study. Group 1 consisted of 18 patients suffering from chronic bronchitis. All had cough and sputum occurring on most days for more than three months in the year for at least two years, and all complained of distressing wheeze and breathlessness. These patients were selected from the many chronic bronchitic patients admitted to the Respiratory Disease Unit at Edinburgh over a period of two years. They were chosen because of their distressing wheeze and because I thought that such a group might show more objective response to bronchodilator drugs than an unselected group of patients with chronic bronchitis. There were 12 men and 6 women in this group. Their ages ranged from 36 to 71 years (men 45 to 71 years and women 36 to 67 years). Eleven patients were cigarette smokers at the time of the study. Four patients had been cigarette smokers but had stopped prior to the study. Three of the women had never smoked. Group 2 consisted of 18 patients with chronic asthma who were not at the time of the study being treated with corticosteroid drugs. In the selection of this group of patients, certain features of their history were used to diagnose chronic asthma as opposed to chronic bronchitis. Particular attention was paid to the mode of development, nocturnal exaggeration of symptoms as opposed to wheeze on getting up in the morning, and the smoking habits.
There were 14 men and 4 women in this group. Their ages ranged from 32 to 68 years (men 34 to 68 years and women 32 to 44 years). One patient in this group was a cigarette smoker at the time of the study; nine had stopped smoking; seven gave no smoking history; and one was a pipe smoker.
Both groups were chosen on purely clinical grounds. The results of previous ventilatory function tests, if they had been performed, were not taken into consideration. Full details of the patients are given in Tables I and II , and pretreatment F.E.V. levels are recorded.
METHODS
The following drugs and methods of administration were used: (1) Isoprenaline sulphate 2% inhalation (2) Adrenaline HCI 1:100 inhalation (3) Adrenaline HCI 1:1 ,000 subcutaneous injection (0-5 ml.) (4) Aminophylline intravenous injection (0-5 g.) (5) Atropine sulphate subcutaneous injection (0-6 mg.) (6) Saline inhalation. The inhalations were given using a Wright nebulizer for three minutes with an oxygen flow rate of 8 litres per minute.
The order of drug administration was randomized by the use of Latin squares, the drug sequence for each patient not being known until the morning of the first test. All tests were performed by the author on consecutive mornings between the hours of 8 a.m. and 10 a.m. in order to avoid diurnal variation in tests of respiratory function (Lewinsohn, Capel, and Smart, 1960) . The one-second forced expiratory volume (F.E.V.i.o) was recorded using a modified Gaensler spirometer (McKerrow, McDermott, and Gilson, 1960) . Three recordings of the F.E.V.l.o were made before the drugs were given and again 20 minutes after drug administration. The best of the three F.E.V.1.o recordings was accepted.
After the six tests had been completed, prednisolone, 40 me. daily, was given and daily recordings of three F.E.V.1.o measurements were made on six consecutive mornings.
Some of the patients were receiving bronchodilator drugs as part of their routine ward treatment, but these drugs were not administered until after the morning test had been performed. The patients who had their own 'inhalers' were instructed not to use them after 4 a.m. and only short-acting preparations containing isoprenaline alone were allowed to avoid any possible carry-over effect of inhalations containing isoprenaline and atropine methonitrate.
RESULTS
The responses to the six drugs used in the first part of the study were calculated as changes in F.E.V.1.0 expressed as percentages of the pretreatment values. A single pretreatment value was chosen in preference to a mean of all the values in the previous week, because a number of the asthmatic patients showed some spontaneous improvement in their F.E.V. readings during the week before prednisolone was administered, and therefore a mean of all the values during the first week would have tended to exaggerate the prednisolone response. Also during prednisolone therapy the changes in F.E.V.1.0 over the period of six days were expressed as percentages of the preprednisolone treatment values. following the administration of the antispasmodic drlags, saline hbi inhalation, and prednisolone. Figure I shows the mean changes in F.E.V.1.,, for the 18 patients in the bronchitic group following the administration of the six test drugs and prednisolone. There is no significant difference between the responses to all five of the active substances used in the first part of the study. The mean improvement in F.E.V.,.,, ranged from 24-1 0 after adrenaline inhalation to 325%o following atropine sulphate. There was a mean improvement in F.E.V.I. after saline inhalation of 0-2",.
During the six-day period of prednisolone administration slight improvement occurred, which reached a mean value of 11-70, after six days. This improvement is not significant (P> 0 05<011). Figure 2 shows the mean changes in F.E.V.1., for the 18 patients in the asthmatic group following the administration of the six test drugs and prednisolone. There is considerable variation between the responses to the six drugs used in the first part of the study. The mean improvement in F.E.V., following administration of these drugs was 44°', after subcutaneous adrenaline, 34 3 0,/, after isoprenaline inhalation, 320,, after intravenous aminophylline, 23 7 0 after adrenaline inhalation, 17 1"(/, after subcutaneous atropine sulphate, and 23o% after saline inhalation. The difference between the mean response to subcutaneous adrenaline and isoprenaline inhalation is not significant (P=0 2), nor is the difference between the mean response to subcutaneous adrenaline and intravenous aminophylline (P= 01). There are significant differences between the mean F.E.V.,.,, responses following subcutaneous adrenaline and adrenaline inhalation (P=0-005) and subcutaneous atropine (P<0 001). group.bmj.com on June 24, 2017 -Published by http://thorax.bmj.com/ Downloaded from significant improvement of 25-5% (P<0 01>0001) occurred after 24 hours and rose to 49-5% after six days' treatment (P<0-001).
All patients in both groups had a differential white cell count performed before the administration of prednisolone, and all patients, except for one in the chronic asthma group who had no sputum, had three specimens of sputum examined microscopically for eosinophils. One patient in the chronic bronchitic group had a significant increase of eosinophils in the peripheral blood, though none in this group had eosinophils in the three specimens of sputum examined.' In contrast, four patients in the chronic asthma group had a significant peripheral blood eosinophilia, two had eosinophils in the sputum, and a further two had both eosinophils in the sputum and blood eosinophilia.
The eight patients in the chronic asthma group with sputum or blood eosinophilia or both did not respond significantly better to prednisolone than the 10 patients in whom no eosinophilia was demonstrated. The mean improvement in F.E.V.1.), of the patients with eosinophilia after six days' prednisolone treatment was 53 4%, compared with 47-20%o for the patients without eosinophilia (P> 08<09).
DISCUSSION
Strikingly different results were obtained in the two groups of patients studied. In the chronic bronchitics (group 1) the similarity of theresponses to the short-acting bronchodilator drugs is impressive. There was a slightly greater improvement in the mean F.E.V.,.0 after atropine sulphate, compared with the mean responses to the other drugs, but this was not statistically significant. In an independent study of patients with chronic bronchitis it was found that the improvement in F.E.V.1.0 following the administration of atropin2 sulphate subcutaneously continued for at least one hour ( Fig. 3 and Table III no further improvement was observed at 30 minutes after administration of the drugs (Fig. 4) . The improvement in the F.E.V. The responses to the short-acting bronchodilator drugs in the group of patients with chronic asthma (group 2) differed markedly from the group 1 results. The greatest improvement in the mean F.E.V.1.0 occurred after subcutaneous adrenaline, but this response was not significantly greater than the mean F.E.V.,lo improvement following isoprenaline inhalation or intravenous aminophylline. The significant difference between the mean F.E.V.1., responses to subcutaneous adrenaline and adrenaline inhalation is not in accord with the work of Kennedy (1961) , who reports that both methods of administration of adrenaline cause similar responses in asthmatic patients. The inhalation dose of adrenaline used in the present study was large approximately 3 mg. delivered from the Wright nebulizer to the face mask and hence it is unlikely that a small dose of adrenaline was responsible for the relatively poor mean response to adrenaline inhalation. Following the inhalation of adrenaline the response is maintained for longer than 20 minutes, and hence the time of F.E.V.1.O, recording can be excluded as a cause of this difference between the mean responses following inhalation and injection of adrenaline.
The patients selected were not severely disabled by their wheeze and breathlessness at the time of the study. None of the chronic asthma patients selected was ill enough to require immediate treatment with prednisolone. The mean F.E.V.1.o of the asthma patients before the first treatment was 1,340 ml., and only slight daily fluctuation of the mean basal FEV.V,1 occurred during the six days of the first part of the study (range 1,300 to 1,400 ml.). As the patients were not in a severe stage of the disease and there was only slight daily fluctuation in the mean pre-treatment F.E.V.1., values, it can be assumed that adrenaline inhalation was not given at a time when the patient's asthma was so severe that a poor response could be expected (Hume and Gandevia, 1957; Kennedy, 1961 (Pearson, 1958; Herxheimer, 1959) . When the responses to the active drugs in the chronic bronchitic and the asthmatic groups are compared, the outstanding difference is in the response to atropine-a good response in the bronchitic group and a poor response in the asthmatic group. A good response to subcutaneous adrenaline was observed in both groups. When the responses to subcutaneous adrenaline and atropine in both groups are considered together with the insignificant improvement after prednisolone in group 1 and the good response to prednisolone in group 2, it is tempting to postulate that a significantly better response to subcutaneous adrenaline than to subcutaneous atropine is more in favour of an expected satisfactory prednisolone response than are equally good responses to subcutaneous adrenaline and subcutaneous atropine. The numbers of patients studied were small, however, and some variations of the subcutaneous adrenaline and atropine responses occurred within the groups. This is worthy of further study, since a poor response to aerosol atropine compared with aerosol isoprenaline has been observed in patients whose airways obstruction responds to corticosteroids, and similar responses to aerosol atropine and isoprenaline in patients whose bronchospasm was unaffected by corticosteroid therapy have also been reported (Altounyan, 1964; Gandevia, 1965) . Aerosol atropine methonitrate produces a more rapid response in patients regarded as having chronic bronchitis than in patients with uncomplicated asthma (Gandevia, 1965 (Freedman, 1963; Cullen and Reidt, 1960; Lorriman, 1959) . Some of the patients did, however, experience subjective improvement out of all proportion to the ventilatory improvement recorded.
The mean F.E.V.1.0 response to prednisolone of the chronic asthmatic patients, which reached a value of 49-5% after six days' treatment, was not unexpected, as patients suffering from chronic asthma can be expected to respond to corticosteroid drugs (Thursby-Pelham and Kennedy, 1958; Somner et al., 1960; Phear et al., 1960) .
The different responses to prednisolone in the two groups are evidence in favour of a correct initial clinical diagnosis of chronic bronchitis and chronic asthma.
Eight of the 18 patients with chronic asthma studied were found to have sputum eosinophilia and/or significant peripheral blood eosinophilia.
It has been reported that asthmatic patients with sputum eosinophilia respond well to corticosteroid therapy (Brown, 1958) . In this study the patients with eosinophilia did not respond significantly better to prednisolone than did those in whom no eosinophilia was demonstrated.
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